Galapagos was founded in 1999 as a joint venture between Crucell and Tibotec. In May 2005, the Company listed on Euronext Brussels and Amsterdam (ticker symbol: GLPG). In 2006, Galapagos acquired ProSkelia in Romainville, France, obtaining R&D operations there. In 2010, Galapagos acquired the Zagreb research operations from GSK; this site became Fidelta, a drug discovery fee-for-service business within the Galapagos group. Fidelta was acquired by Selvita in 2021.

Click for full size image

In 2014 Galapagos sold fee-for-service businesses BioFocus and Argenta to Charles River Laboratories International, Inc., giving Galapagos a sole focus on the development and execution of a broad and deep R&D pipeline based on novel mechanisms-of-action. 

Galapagos listed on the US NASDAQ (ticker symbol: GLPG) in May 2015.

In 2015, Galapagos signed a collaboration agreement with Gilead for the development and commercialization of filgotinib.

In 2019, Galapagos entered into a transformative 10-year global research and development collaboration with Gilead.

In 2020, Jyseleca® was granted marketing authorization for the treatment of rheumatoid arthritis (RA) in the European Union, Great Britain and Japan, marking Galapagos’ transition to commercial-stage biotech. A year later, in 2021, the European Commission and Great Britain’s Medicines and Healthcare products Regulatory Agency approved the medicine for the treatment of ulcerative colitis (UC), followed by an approval by the Japanese authorities in 2022.

In 2021, Galapagos took full ownership of the manufacturing and commercialization of Jyseleca in Europe and became Marketing Authorization Holder (MAH) in 27 European countries, Iceland, Norway, and Liechtenstein. In Central and Eastern Europe, Portugal, Greece and the Baltic countries, Galapagos’ partner Sobi is responsible for the distribution and commercialization.

In June 2022, Galapagos announced the acquisition of CellPoint and AboundBio, propelling Galapagos into next-generation cell therapy while significantly broadening its portfolio and capabilities. With CellPoint and AboundBio, Galapagos gains access to a scalable, decentralized and automated point-of-care cell therapy supply model, a clinical pipeline in advanced blood cancers as well as a human antibody-based therapeutics platform. The acquisition of both companies is a first key step in the company’s strategic transformation to accelerate and diversify Galapagos’ pipeline.